Results 311 to 320 of about 596,620 (345)

Prognosis of follicular lymphomas

Hematological Oncology, 2006
AbstractFollicular lymphoma (FL) is as an indolent neoplasia with median survival measured in decades. Nevertheless, some patients have poor progression‐free survival and overall survival. Several treatment approaches are proposed for patients with FL, however criteria to rationalize treatment decisions are lacking. Studies have been performed to build
LUMINARI, Stefano, FEDERICO, Massimo
openaire   +2 more sources

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.

The Lancet Haematology, 2018
BACKGROUND Histological transformation of follicular lymphoma to aggressive lymphoma is a serious event with a substantial effect on patient outcome.
M. Federico, M. D. Caballero Barrigón, L. Marcheselli, V. Tarantino, M. Manni, C. Sarkozy, S. Alonso-Álvarez, M. Wondergem, G. Cartron, A. López-Guillermo, D. Issa, F. Morschhauser, M. Alcoceba, E. Kimby, C. Rusconi, M. Chamuleau, H. Holte, S. Lockmer, S. Montoto, M. Gomes da Silva, I. Aurer, E. Zucca, E. Paszkiewicz-Kozik, C. Minoia, T. Skrypets, Y. Blaker, G. Salles, B. Coiffier   +27 more
semanticscholar   +1 more source

Cutaneous Follicular Lymphoma

The American Journal of Surgical Pathology, 1986
Fifteen cases of cutaneous follicular lymphoma were evaluated clinically, histologically, and immunologically. Nine of the patients presented with skin disease alone, which showed a predilection for the scalp and forehead. The six remaining cases had either concurrent or secondary cutaneous involvement.
C F, Garcia, L M, Weiss, R A, Warnke, G S, Wood   +3 more
openaire   +2 more sources

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.

The Lancet Oncology, 2022
L. Budde, L. Sehn, M. Matasar, S. Schuster, S. Assouline, P. Giri, J. Kuruvilla, M. Canales, S. Dietrich, K. Fay, M. Ku, L. Nastoupil, C. Cheah, M. Wei, S. Yin, Chi-Chung Li, Huang Huang, A. Kwan, E. Penuel, N. Bartlett   +19 more
semanticscholar   +1 more source

Follicular lymphoma and the microenvironment

Blood, 2008
In this issue of Blood , Byers and colleagues validate the role of immune signatures for prognosis in follicular lymphoma by applying RT-PCR.
openaire   +2 more sources

The curability of follicular lymphoma

Transfusion and Apheresis Science, 2007
Follicular lymphoma has been widely thought to be an incurable disease. However, if cure is defined as a remission that continues indefinitely and the patient eventually dies of another disease, some patients with follicular lymphoma are cured. Follicular lymphoma grade 3 acts much like diffuse large B-cell lymphoma, and cure is frequent.
Matthew, Lunning, James O, Armitage
openaire   +2 more sources

Immunopathology of Follicular Lymphomas

New England Journal of Medicine, 1978
To the Editor: In their article in the March 2 issue of the Journal Warnke and Levy propose that reactive lymphoid follicles can be differentiated from lymphoma nodules by the characterization of immunoglobulin light chains in direct immunofluorescence. There are several arguments against this approach.
D B, Brubaker, T L, Whiteside
openaire   +2 more sources

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nature Medicine, 2021
N. Fowler, M. Dickinson, M. Dreyling, J. Martínez-López, A. Kolstad, J. Butler, M. Ghosh, L. Popplewell, J. Chavez, E. Bachy, Koji Kato, H. Harigae, M. Kersten, C. Andreadis, P. Riedell, P. Ho, J. Pérez-Simón, Andy I. Chen, L. Nastoupil, B. von Tresckow, A. Ferreri, T. Teshima, P. Patten, J. Mcguirk, A. Petzer, F. Offner, A. Viardot, P. Zinzani, R. Malladi, A. Zia, R. Awasthi, Aisha Masood, O. Anak, S. Schuster, C. Thieblemont   +34 more
semanticscholar   +1 more source

Advances in follicular lymphoma

Seminars in Oncology, 2004
Follicular lymphoma is a usually indolent lymphoma that responds well to chemotherapy. While multiple treatments show a good response rate, most patients relapse. Emerging therapies, such as antibody therapy and stem cell transplantation, are increasingly being used to try to lengthen response time. This article will review the available treatments for
Travis D, Archuleta, James O, Armitage
openaire   +2 more sources

Follicular Lymphoma Revisited

Journal of Clinical Oncology, 2008
The last quarter century has seen significant advances in the management and understanding of many human malignancies. This is especially true for the malignant lymphomas. The invitation to reflect on a report from Stanford, published 25 years ago, and the changes that have occurred since then, is a rare opportunity to look at what we have learned ...
openaire   +2 more sources